[Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of riamilovir in the treatment of COVID-19].

A U Sabitov Dmitriy A Lioznov K V Zhdanov E P Tihonova E V Esaulenko O P Kovtun P L Kuznetsov P V Sorokin

Published in: Terapevticheskii arkhiv (2024)

As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for therapeutic use in patients with COVID-19 according to the 1250 mg/day scheme (250 mg capsules 5 times per day) for 10 days was established. The drug riamilovir in a daily dose of 1250 mg for 10 days does not differ in safety from placebo.

Keyphrases

double blind
clinical trial
placebo controlled
phase iii
phase ii
coronavirus disease
study protocol
sars cov
open label
randomized controlled trial
systematic review
physical activity
drug induced
adverse drug
emergency department
respiratory syndrome coronavirus